WO2022019626A1 - 대장암 전이 억제제 스크리닝 방법 - Google Patents
대장암 전이 억제제 스크리닝 방법 Download PDFInfo
- Publication number
- WO2022019626A1 WO2022019626A1 PCT/KR2021/009367 KR2021009367W WO2022019626A1 WO 2022019626 A1 WO2022019626 A1 WO 2022019626A1 KR 2021009367 W KR2021009367 W KR 2021009367W WO 2022019626 A1 WO2022019626 A1 WO 2022019626A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- icam
- colorectal cancer
- src
- cancer metastasis
- expression
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 89
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims abstract description 39
- 238000012216 screening Methods 0.000 title claims abstract description 15
- 239000002257 antimetastatic agent Substances 0.000 title claims description 10
- 239000000463 material Substances 0.000 claims abstract description 10
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 60
- 206010027476 Metastases Diseases 0.000 claims description 48
- 230000009401 metastasis Effects 0.000 claims description 48
- 208000029742 colonic neoplasm Diseases 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 238000003752 polymerase chain reaction Methods 0.000 claims description 18
- 108020004999 messenger RNA Proteins 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000003753 real-time PCR Methods 0.000 claims description 11
- 238000003757 reverse transcription PCR Methods 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 238000000636 Northern blotting Methods 0.000 claims description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 6
- 102000006382 Ribonucleases Human genes 0.000 claims description 6
- 108010083644 Ribonucleases Proteins 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 6
- 108091023037 Aptamer Proteins 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims description 3
- 108020005544 Antisense RNA Proteins 0.000 claims description 3
- 108700011259 MicroRNAs Proteins 0.000 claims description 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 239000003184 complementary RNA Substances 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 239000002679 microRNA Substances 0.000 claims description 3
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- 229930014626 natural product Natural products 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000002924 silencing RNA Substances 0.000 claims description 3
- 239000004055 small Interfering RNA Substances 0.000 claims description 3
- 108700026239 src Genes Proteins 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 abstract description 33
- 230000001394 metastastic effect Effects 0.000 abstract description 13
- 206010061289 metastatic neoplasm Diseases 0.000 abstract description 13
- 230000001419 dependent effect Effects 0.000 abstract description 12
- 229940124597 therapeutic agent Drugs 0.000 abstract description 6
- 239000012830 cancer therapeutic Substances 0.000 abstract description 4
- 230000001747 exhibiting effect Effects 0.000 abstract description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 abstract 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 27
- 201000011510 cancer Diseases 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 16
- 230000003247 decreasing effect Effects 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000012790 confirmation Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 210000004534 cecum Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002491 angiogenic effect Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 238000012744 immunostaining Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000237858 Gastropoda Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- -1 morpholino (morpholino) Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102100025805 Cadherin-1 Human genes 0.000 description 1
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 1
- 208000018458 Colitis-Associated Neoplasms Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 101150074545 Zeb1 gene Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Definitions
- the present invention relates to a colon cancer metastasis inhibitor screening method, and more particularly, to a colorectal cancer metastasis inhibitor screening method in which a substance that increases the binding level of ICAM-1 and SRC is selected as a therapeutic substance.
- Colorectal cancer is the third most commonly diagnosed cancer in the world and the fourth most common cause of death. Colorectal cancer can be classified into sporadic colon cancer and colitis associated colorectal cancer depending on the onset factor. Sporadic colorectal cancer is caused by several factors such as genetic factors, aging, type 2 diabetes, overweight, drinking and smoking, and inflammatory colorectal cancer is a persistent inflammatory bowel disease such as Crohn's disease and ulcerative colitis. (Inflammatory bowel disease) is the main cause. Since sporadic colorectal cancer is mostly caused by aging or genetic factors, it mainly appears in elderly patients. However, inflammatory colorectal cancer is more likely to occur in younger patients and is known to have a higher mortality rate than sporadic colorectal cancer.
- colonoscopy is a common screening method for identifying and removing polyps, but it causes many side effects, such as intestinal perforation, intestinal bleeding, and sleep apnea, and there are many difficulties in accurately selecting tumors. Therefore, there is a need to develop a marker for diagnosing or treating colorectal cancer.
- the present inventors completed the present invention by confirming that ICAM-1 regulates cancer metastasis and angiogenesis in a SRC-dependent manner as a result of researching on a candidate colorectal cancer metastasis inhibitor.
- an object of the present invention is to provide a method for screening a colon cancer metastasis inhibitor.
- Another object of the present invention is to provide a composition for predicting colon cancer metastasis comprising an agent for measuring the mRNA level of the ICAM-1 gene or an agent for measuring the protein level encoded by the gene.
- the present invention comprises the steps of (a) treating a candidate material in cells in Vitro; (b) measuring the level of binding between intracellular adhesion molecule 1 (ICAM-1) and SRC in the cell; And (c) provides a colon cancer metastasis inhibitor screening method comprising the step of selecting a substance that increases the binding level of ICAM-1 and SRC compared to the untreated group of the candidate substance as a therapeutic substance.
- ICAM-1 intracellular adhesion molecule 1
- the cell may be a colorectal cancer cell.
- the candidate material may be selected from the group consisting of compounds, microbial cultures or extracts, natural product extracts, nucleic acids, and peptides.
- the nucleic acid is siRNA, shRNA, microRNA, antisense RNA, aptamer (aptamer), LNA (locked nucleic acid), PNA (peptide nucleic acid), and morpholino (morpholino) consisting of can be selected from the group.
- the measurement of the binding level of ICAM-1 and SRC may be measuring the mRNA level of ICAM-1 and SRC genes.
- the mRNA level is polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), real-time polymerase chain reaction (Real-time PCR), RNase protection assay (RNase protection) assay; RPA), microarray, and northern blotting (northern blotting) can be measured through one or more methods selected from the group consisting of.
- the present invention provides a composition for predicting colon cancer metastasis comprising an agent for measuring the mRNA level of the ICAM-1 gene or an agent for measuring the protein level encoded by the gene.
- the present invention provides a pharmaceutical composition for inhibiting colon cancer metastasis comprising the ICAM-1 gene or a protein encoded by the gene as an active ingredient.
- the present invention showed that ICAM-1 could be a potential target for the development of a treatment for colorectal cancer by confirming that ICAM-1 can regulate cancer metastasis and angiogenesis in an SRC-dependent manner. Accordingly, it is possible to increase the therapeutic effect of colorectal cancer patients by using the colorectal cancer therapeutic agent using the target screened by the method of the present invention.
- 1a is a result of confirming the difference in ICAM-1 expression between normal people and inflammatory bowel disease patients.
- Figure 1b is the result of confirming the difference in ICAM-1 expression in normal people and cancer patients.
- 1d is a normal cell line CCD841 and colon cancer cell lines (HT-29, HCT-116, SW-620, SW-480, DLD-1) by performing real-time PCR, the expression level of ICAM-1 in colorectal cancer cells is the result of checking
- 1e and 1f are results of confirming the relationship between colorectal cancer malignancy and ICAM-1 through the CPTAC data base and colorectal cancer patient tissue data.
- 1I and 1J are results of confirming the expression level of ICAM-1 in a patient who has metastasized to a lymph node.
- Figure 2a is a result of confirming the relationship between the high expression level of ICAM-1 and tumor metastasis and angiogenesis using GSEA analysis.
- Figure 2b is a schematic diagram illustrating a method of injecting the SW-480 cell line with reduced ICAM-1 expression into the cecum of mice.
- FIG. 2c is a result confirming the relationship between ICAM-1 expression and tumor metastasis in the mouse transplanted with the SW-480 cell line in FIG. 2b.
- 2D and 2E are results of confirming the expression levels of EMT markers and metastasis factors in mice transplanted with the SW-480 cell line of FIG. 2B.
- Figure 2f is the result of confirming the relationship between the expression level of ICAM-1 and angiogenesis in vitro.
- 2G and 2H are results of confirming the relationship between the expression level of ICAM-1 and the angiogenesis ability in vivo in the mouse model of FIG. 2B through PCR and tissue immunofluorescence.
- 3a is a result of confirming the correlation with p-SRC by performing a kinase array for ICAM-1.
- 3b and 3c are results of confirming SRC activity according to ICAM-1 expression through the TCGA database for colorectal cancer patients.
- 3d is a result of confirming the interaction between ICAM-1 and SRC using the immunoprecipitation method.
- 3e is a result of confirming the binding position of SRC to ICAM-1 by performing tissue immunofluorescence to confirm the interaction between ICAM-1 and SRC in detail.
- 3f and 3g show the results of confirming the relationship between tumor metastasis and angiogenesis after constructing a mutant that inhibits or activates the Tyr512 residue of ICAM-1.
- Figure 4a is the result of confirming the gene exhibiting high expression in common in colorectal cancer patients through four GEO databases.
- Figure 4b is a result of specifically confirming the expression of ICAM-1 and SRC after treatment with a c-MET inhibitor.
- Figure 4c is a result of confirming the expression level of p-SRC when the ICAM-1 expression is suppressed and then treated with HGF, a ligand of c-MET.
- 4d is a result confirming the activation of SRC in the mutant overexpressing ICAM-1.
- 4e and 4f are results of observing the binding level of c-MET and SRC according to the reduction of ICAM-1 through IP and PLA.
- Figure 4g is a result of confirming the expression level of p-SRC through ICC when ICAM-1 and c-MET are present at the same position.
- 5a is a result of confirming metastatic potential when ICAM-1 is overexpressed and then SRC is knocked down.
- 5b and 5c are results of confirming the expression levels of EMT markers and transcription factors through real-time PCR and western blot when SRC is knocked down after overexpressing ICAM-1.
- 5d, 5e, and 5f are results of confirming the angiogenic ability and the expression of growth factors that induce the angiogenesis when SRC is knocked down after overexpressing ICAM-1.
- Figure 5g is a result of confirming the correlation between the expression level of ICAM-1 and p-SRC in the tissue of a colorectal cancer patient.
- 5h is the result of confirming the correlation between the expression level of ICAM-1 and p-SRC and the prognosis of colorectal cancer patients.
- Figure 6a is the result of confirming the metastatic ability of the tumor when 3 weeks have elapsed after injecting the tumor into the cecum, and then injecting the monoclonal antibody into the abdominal cavity.
- 6b and 6c show the results of confirming the expression level of metastasis-related genes by PCR and tissue immunostaining when 3 weeks have elapsed after the tumor was injected into the cecum.
- Figure 6d is the result of confirming the angiogenic ability of the blood vessel when the SW-480 cell line is treated with a monoclonal antibody.
- 6e and 6f are results of observing the expression level and angiogenesis level of growth factors regulating angiogenesis in vivo in the case of monoclonal antibody treatment.
- 6a is a result of confirming the survival rate of colorectal cancer according to ICAM-1 expression.
- 6b is a result of analyzing colorectal cancer grade according to ICAM-1 expression.
- 6c shows the results of analyzing the tumor size according to ICAM-1 expression.
- Figure 6d confirms the correlation between ICAM-1 and p-SRC in the tissue of a colorectal cancer patient.
- 6e is a result confirming the prognosis according to the increase in the expression of ICAM-1 and p-SRC.
- 7a is a result of injecting a tumor into the cecum, then injecting a monoclonal antibody into the abdominal cavity and confirming the metastatic ability of the tumor.
- 7B and 7C are results of confirming the expression level of metastasis-related genes through PCR and tissue immunostaining after injecting the tumor into the cecum.
- Figure 7d is the result of confirming the angiogenesis ability of SW-480 cell line after treatment with ICAM-1 monoclonal antibody.
- 7e and 7f are results of confirming the expression of factors regulating angiogenesis in vivo and the number of new blood vessels.
- the present inventors completed the present invention by confirming that ICAM-1 regulates cancer metastasis and angiogenesis in a SRC-dependent manner as a result of research on colorectal cancer metastasis inhibitor candidates.
- the present invention comprises the steps of: (a) treating cells with a candidate material in Vitro; (b) measuring the level of binding between intracellular adhesion molecule 1 (ICAM-1) and SRC in the cell; And (c) provides a colon cancer metastasis inhibitor screening method comprising the step of selecting a substance that increases the binding level of ICAM-1 and SRC compared to the untreated group of the candidate substance as a therapeutic substance.
- ICAM-1 intracellular adhesion molecule 1
- colorectal cancer metastasis inhibitor means not only to inhibit the proliferation of cells caused by colon cancer, but also to inhibit metastasis and mobility of colon cancer.
- the colorectal cancer metastasis inhibitor may include any molecule such as, for example, proteins, oligopeptides, small organic molecules, polysaccharides, polynucleotides, and a wide range of compounds.
- the "cell” may be a colon tissue-derived cell, but is not limited thereto, and is used to compare the binding level of ICAM-1 and SRC, and preferably may be a colon cancer cell, but is not limited thereto. it is not
- the term “candidate material” refers to a material expected to increase the binding level of ICAM-1 and SRC, and the candidate material is a compound, a microbial culture medium or extract, a natural product extract, a nucleic acid, and a peptide consisting of It may be selected from the group, but is not limited thereto.
- the nucleic acid may be selected from the group consisting of siRNA, shRNA, microRNA, antisense RNA, aptamer, LNA (locked nucleic acid), PNA (peptide nucleic acid), and morpholino.
- the present invention is not limited thereto.
- the measurement of the binding level of ICAM-1 and SRC according to the present invention may be measuring the mRNA level of ICAM-1 and SRC genes.
- the mRNA level is polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), real-time polymerase chain reaction (Real-time PCR), RNase protection assay (RPA), micro
- PCR polymerase chain reaction
- RT-PCR reverse transcription polymerase chain reaction
- Real-time PCR real-time polymerase chain reaction
- RNase protection assay micro
- microarray microarray
- northern blotting microblotting
- the present inventors have identified that ICAM-1 regulates metastatic potential and angiogenesis in a SRC-dependent manner through specific examples.
- ICAM-1 is involved in the metastatic and angiogenic ability of colorectal cancer, and it can be inferred that the colorectal cancer inhibitory effect of ICAM-1 is regulated in a SRC-dependent manner.
- the present invention provides a composition for predicting colon cancer metastasis comprising an agent for measuring the mRNA level of the ICAM-1 gene or an agent for measuring the protein level encoded by the gene, and a kit comprising the same do.
- the ICAM-1 gene may consist of the nucleotide sequence of SEQ ID NO: 2, and homologues of the nucleotide sequence are also included within the scope of the present invention.
- the gene includes a nucleotide sequence having a sequence homology of 70% or more, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more to the nucleotide sequence of SEQ ID NO: 2, respectively.
- the protein encoded by the ICAM-1 gene may consist of the amino acid sequence of SEQ ID NO: 1, and is interpreted to include a sequence showing substantial identity to the sequence shown in SEQ ID NO: 1.
- the substantial identity is at least 80% when the aligned sequence is analyzed using an algorithm commonly used in the art after aligning the sequence of the present invention with any other sequence as much as possible.
- a sequence exhibiting homology more preferably 90%, 91%, 92%, 93%, 94%, 95% homology, most preferably 96%, 97%, 98%, 99% homology. it means.
- the agent for measuring the mRNA level may be sense and antisense primers or probes that complementarily bind to the mRNA of a gene.
- primer refers to an oligonucleotide synthesized for use in diagnosis, DNA sequencing, etc. as a short gene sequence serving as a starting point of DNA synthesis.
- the primers may be synthesized and used with a length of typically 15 to 30 base pairs, but may vary depending on the purpose of use, and may be modified by methylation, capping, etc. by a known method.
- probe refers to a nucleic acid capable of specifically binding to mRNA having a length of several bases to several hundreds of bases produced through enzymatic, chemical separation, purification or synthesis.
- the presence or absence of mRNA can be checked by labeling radioactive isotopes or enzymes, and it can be designed and modified by a known method.
- the agent for measuring the protein level may be an antibody that specifically binds to a protein encoded by a gene, but is not limited thereto.
- antibody includes immunoglobulin molecules having immunological reactivity with a specific antigen, and includes both monoclonal and polyclonal antibodies.
- the antibody also includes forms produced by genetic engineering such as chimeric antibodies (eg, humanized murine antibodies) and heterologous antibodies (eg, bispecific antibodies).
- the kit for prediction of the present invention consists of one or more other component compositions, solutions or devices suitable for the analysis method.
- the kit of the present invention contains genomic DNA derived from a sample to be analyzed, a primer set specific for the marker gene of the present invention, an appropriate amount of a DNA polymerase, a dNTP mixture, a PCR buffer, and water to perform PCR. It may be a kit comprising
- the PCR buffer solution may contain KCl, Tris-HCl and MgCl 2 .
- components necessary for performing electrophoresis that can confirm whether or not the PCR product is amplified may be additionally included in the kit of the present invention.
- the kit of the present invention may be a kit including essential elements necessary for performing RT-PCR.
- the RT-PCR kit includes a test tube or other suitable container, reaction buffer, deoxynucleotides (dNTPs), enzymes such as Taq-polymerase and reverse transcriptase, DNase, RNase inhibitors, DEPC -Water (DEPC-water), sterile water, etc. may be included.
- dNTPs deoxynucleotides
- enzymes such as Taq-polymerase and reverse transcriptase
- DNase DNase
- RNase inhibitors DEPC -Water
- sterile water etc.
- a primer pair specific for a gene used as a quantitative control may be included.
- the kit of the present invention may be a kit including essential elements necessary for performing a DNA chip.
- the DNA chip kit may include a substrate to which cDNA corresponding to a gene or fragment thereof is attached as a probe, and the substrate may include cDNA corresponding to a quantitative structural gene or fragment thereof.
- the kit of the present invention may be in the form of a microarray having a substrate on which the marker gene of the present invention is immobilized.
- the kit of the present invention may be a kit characterized in that it includes essential elements necessary for performing ELISA.
- the ELISA kit includes an antibody specific for a marker protein, and an agent for measuring the protein level.
- the ELISA kit may include a reagent capable of detecting an antibody that has formed an "antigen-antibody complex", for example, a labeled secondary antibody, chromopores, an enzyme, and a substrate thereof.
- an antibody specific for the quantitative control protein may be included.
- the term “antigen-antibody complex” refers to a combination of a protein encoded by a gene and an antibody specific thereto.
- the amount of formation of the antigen-antibody complex can be quantitatively measured through the magnitude of the signal of the detection label.
- the detection label may be selected from the group consisting of an enzyme, a fluorescent substance, a ligand, a luminescent substance, a microparticle, a redox molecule, and a radioisotope, but is not limited thereto.
- the present invention provides information for predicting metastasis of colorectal cancer comprising measuring the expression level of the mRNA of the ICAM-1 gene or the protein encoded by the gene in a biological sample derived from a subject.
- the term "information providing method for metastasis prediction of colorectal cancer" used in the present invention is a preliminary step for diagnosis, providing objective basic information necessary for diagnosing colorectal cancer metastasis, and the clinical judgment or opinion of a doctor is excluded. .
- the biological sample derived from the subject may include, but is not limited to, tissues, cells, whole blood, blood, saliva, sputum, cerebrospinal fluid, and urine.
- the expression level of the mRNA is NanoString nCounter analysis, polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), real-time polymerase chain reaction (Real-time PCR), RNase protection It may be measured by at least one method selected from the group consisting of RNase protection assay (RPA), microarray, and northern blotting, but is not limited thereto.
- PCR polymerase chain reaction
- RT-PCR reverse transcription polymerase chain reaction
- Real-time PCR real-time polymerase chain reaction
- RNase protection RPA
- microarray microarray
- northern blotting but is not limited thereto.
- the protein expression level is determined by western blotting, radioimmunoassay (RIA), radioimmunodiffusion, enzyme immunoassay (ELISA), immunoprecipitation according to a conventional method known in the art. ), flow cytometry, immunofluorescence, ouchterlony, complement fixation assay, and at least one method selected from the group consisting of a protein chip It may be measured through, but is not limited thereto.
- the present invention provides a pharmaceutical composition for inhibiting colon cancer metastasis comprising the ICAM-1 gene or a protein encoded by the gene as an active ingredient.
- metastasis inhibition refers to any action that delays the onset of colon cancer, including inhibition of metastasis and angiogenesis, of colon cancer by administration of the pharmaceutical composition according to the present invention.
- the pharmaceutical composition according to the present invention includes the ICAM-1 gene or a protein encoded by the gene as an active ingredient, and may further include a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier is commonly used in formulation, and includes, but is not limited to, saline, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, liposome, and the like. It does not, and may further include other conventional additives, such as antioxidants and buffers, if necessary.
- diluents, dispersants, surfactants, binders, lubricants, etc. may be additionally added to form an injectable formulation such as an aqueous solution, suspension, emulsion, etc., pills, capsules, granules or tablets.
- the pharmaceutical composition of the present invention may be administered orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally or locally applied) according to a desired method, but preferably may be administered orally, and the dosage Although it varies depending on the condition and weight of the patient, the degree of disease, the drug form, the route and time of administration, it may be appropriately selected by those skilled in the art.
- the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount sufficient to treat or diagnose a disease at a reasonable benefit/risk ratio applicable to medical treatment or diagnosis, and the effective dose level is determined by the patient's disease type, severity, drug activity, sensitivity to drugs, administration time, administration route and excretion rate, treatment period, factors including concurrent drugs, and other factors well known in the medical field.
- the pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple. In consideration of all of the above factors, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, which can be easily determined by those skilled in the art.
- the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, condition, weight, absorption of the active ingredient into the body, inactivation rate and excretion rate, disease type, and drugs used in combination, in general 0.001 to 150 mg, preferably 0.01 to 100 mg per 1 kg of body weight, may be administered daily or every other day, or may be administered in divided doses 1 to 3 times a day.
- the dosage since it may increase or decrease depending on the route of administration, the severity of obesity, sex, weight, age, etc., the dosage is not intended to limit the scope of the present invention in any way.
- the present invention provides a method for predicting colorectal cancer metastasis using the composition for predicting colorectal cancer metastasis.
- the present invention provides a method for preventing, inhibiting or treating colon cancer metastasis, including a method of administering the pharmaceutical composition to a subject.
- the present invention provides a colorectal cancer metastasis predictive use of the composition for predicting colorectal cancer metastasis.
- the present invention provides a use for preventing, inhibiting or treating colon cancer metastasis of the pharmaceutical composition.
- ICAM-1 As a result of confirming the expression of ICAM-1 based on the GEO database, as shown in Fig. 1a, in GSE4183, it was found that the expression of ICAM-1 was high from the stage of inflammatory bowel disease (IBD), which is the stage of colorectal cancer formation, In GSE59071, it was confirmed that the expression of ICAM-1 was high in Crohn's disease and active ulcerative colitis.
- IBD stage of inflammatory bowel disease
- GSE59071 it was confirmed that the expression of ICAM-1 was high in Crohn's disease and active ulcerative colitis.
- the expression of ICAM-1 as described above gradually increased as the stage of malignancy progressed. It was specifically confirmed through the CPTAC database and colon cancer patient tissues. Through the TCGA database, disease-specific survival (DSS) and overall survival (OS) decrease as the expression level of ICAM-1 increases. It was specifically confirmed that the expression of ICAM-1 was further increased, and the prognosis was worse as shown in FIG.
- ICAM-1 regulates cancer metastasis and angiogenesis in an SRC-dependent manner.
- the degree of cancer malignancy was confirmed through GDC TCGA, and at this time, the T stage was marked according to the size of the tumor among the TNM stages, and each stage is divided into T1, T2, T3, and T4. means more advanced. As a result, as shown in FIG. 6c , it was confirmed that the higher the expression of ICAM-1, the more patients corresponding to T3 and T4 appeared.
- the present invention has shown that ICAM-1 can be a potential target for the development of colorectal cancer therapeutics by confirming that ICAM-1 can regulate cancer metastasis and angiogenesis in an SRC-dependent manner. Accordingly, when the target screened by the method of the present invention is used, it is expected to be usefully utilized in the industrial field for the development of a treatment for colorectal cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Description
Claims (12)
- 하기의 단계를 포함하는, 대장암 전이 억제제 스크리닝 방법:(a) In Vitro 상에서 세포에 후보물질을 처리하는 단계;(b) 상기 세포에서 ICAM-1(Intracellular adhesion molecule 1)과 SRC와의 결합수준을 측정하는 단계; 및(c) 상기 후보물질의 비처리군에 비해 ICAM-1과 SRC의 결합수준을 증가시키는 물질을 치료물질로 선정하는 단계.
- 제1항에 있어서,상기 세포는 대장암 세포인 것을 특징으로 하는, 스크리닝 방법.
- 제1항에 있어서,상기 후보물질은 화합물, 미생물 배양액 또는 추출물, 천연물 추출물, 핵산, 및 펩타이드로 이루어진 군으로부터 선택되는 것을 특징으로 하는, 스크리닝 방법.
- 제3항에 있어서,상기 핵산은 siRNA, shRNA, microRNA, 안티센스 RNA, 앱타머(aptamer), LNA(locked nucleic acid), PNA(peptide nucleic acid), 및 모폴리노(morpholino)로 이루어진 군으로부터 선택되는 것을 특징으로 하는, 스크리닝 방법.
- 제1항에 있어서,상기 ICAM-1과 SRC의 결합수준 측정은 ICAM-1 및 SRC 유전자의 mRNA 수준 또는 상기 유전자가 암호화하는 단백질 수준을 측정함으로써 이루어지는 것을 특징으로 하는, 스크리닝 방법.
- 제5항에 있어서,상기 mRNA 수준은 중합효소연쇄반응(PCR), 역전사 중합효소연쇄반응(RT-PCR), 실시간 중합효소연쇄반응(Real-time PCR), RNase 보호 분석법(RNase protection assay; RPA), 마이크로어레이(microarray), 및 노던 블롯팅(northern blotting)으로 이루어진 군으로부터 선택되는 1종 이상의 방법을 통해 측정되는 것을 특징으로 하는, 스크리닝 방법.
- ICAM-1 유전자의 mRNA 수준을 측정하는 제제 또는 상기 유전자가 암호화하는 단백질 수준을 측정하는 제제를 포함하는, 대장암 전이 예측용 조성물.
- ICAM-1 유전자 또는 상기 유전자가 암호화하는 단백질을 유효성분으로 포함하는, 대장암 전이 억제용 약학 조성물.
- 제7항의 대장암 전이 예측용 조성물을 활용한 대장암의 전이 예측방법.
- 제8항의 약학적 조성물을 개체에 투여하는 방법을 포함하는, 대장암 전이 예방, 억제 또는 치료방법.
- 제7항의 대장암 전이 예측용 조성물의 대장암의 전이 예측용도.
- 제8항의 약학적 조성물의 대장암 전이 예방, 억제 또는 치료용도.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180060202.3A CN116134319A (zh) | 2020-07-20 | 2021-07-20 | 用于筛选结直肠癌转移抑制剂的方法 |
JP2022579115A JP2023535280A (ja) | 2020-07-20 | 2021-07-20 | 大腸癌転移阻害剤をスクリーニングする方法 |
CA3189430A CA3189430A1 (en) | 2020-07-20 | 2021-07-20 | Method for screening colorectal cancer metastasis inhibitor |
EP21845811.5A EP4184166A1 (en) | 2020-07-20 | 2021-07-20 | Method for screening colorectal cancer metastasis inhibitor |
US18/016,752 US20230288399A1 (en) | 2020-07-20 | 2021-07-20 | Method for screening colorectal cancer metastasis inhibitor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0089603 | 2020-07-20 | ||
KR20200089603 | 2020-07-20 | ||
KR10-2021-0095111 | 2021-07-20 | ||
KR1020210095111A KR102549771B1 (ko) | 2020-07-20 | 2021-07-20 | 대장암 전이 억제제 스크리닝 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022019626A1 true WO2022019626A1 (ko) | 2022-01-27 |
Family
ID=79729638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/009367 WO2022019626A1 (ko) | 2020-07-20 | 2021-07-20 | 대장암 전이 억제제 스크리닝 방법 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230288399A1 (ko) |
JP (1) | JP2023535280A (ko) |
KR (1) | KR20230107484A (ko) |
CA (1) | CA3189430A1 (ko) |
WO (1) | WO2022019626A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120067672A (ko) * | 2010-12-16 | 2012-06-26 | 사회복지법인 삼성생명공익재단 | 대장암의 간 전이 진단용 조성물 및 그 용도 |
KR20150041751A (ko) * | 2013-10-08 | 2015-04-17 | 서울대학교산학협력단 | TM4SF5 단백질 및 c-Src 단백질의 결합억제제를 유효성분으로 포함하는 암 예방 및 치료, 또는 암 전이 억제용 조성물 |
KR20170058104A (ko) * | 2015-11-18 | 2017-05-26 | 주식회사 메타신 | Fstl1 단백질을 유효성분으로 함유하는 골대사성 질환 예방 및 치료용 약학적 조성물 |
-
2021
- 2021-07-20 WO PCT/KR2021/009367 patent/WO2022019626A1/ko unknown
- 2021-07-20 CA CA3189430A patent/CA3189430A1/en active Pending
- 2021-07-20 US US18/016,752 patent/US20230288399A1/en active Pending
- 2021-07-20 JP JP2022579115A patent/JP2023535280A/ja active Pending
-
2023
- 2023-06-27 KR KR1020230082324A patent/KR20230107484A/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120067672A (ko) * | 2010-12-16 | 2012-06-26 | 사회복지법인 삼성생명공익재단 | 대장암의 간 전이 진단용 조성물 및 그 용도 |
KR20150041751A (ko) * | 2013-10-08 | 2015-04-17 | 서울대학교산학협력단 | TM4SF5 단백질 및 c-Src 단백질의 결합억제제를 유효성분으로 포함하는 암 예방 및 치료, 또는 암 전이 억제용 조성물 |
KR20170058104A (ko) * | 2015-11-18 | 2017-05-26 | 주식회사 메타신 | Fstl1 단백질을 유효성분으로 함유하는 골대사성 질환 예방 및 치료용 약학적 조성물 |
Non-Patent Citations (3)
Title |
---|
CHEN JIEZHONG, ELFIKY AYMEN, HAN MEI, CHEN CHEN, SAIF M. WASIF: "The Role of Src in Colon Cancer and Its Therapeutic Implications", CLINICAL COLORECTAL CANCER, C I G MEDIA GROUP, L.P., US, vol. 13, no. 1, 1 March 2014 (2014-03-01), US , pages 5 - 13, XP055892657, ISSN: 1533-0028, DOI: 10.1016/j.clcc.2013.10.003 * |
CHRISTINA L ET AL., SURGERY, June 2007 (2007-06-01), pages 705 - 707 |
TACHIMORI, A. ; YAMADA, N. ; SAKATE, Y. ; YASHIRO, M. ; MAEDA, K. ; OHIRA, M. ; NISHINO, H. ; HIRAKAWA, K.: "Up regulation of ICAM-1 gene expression inhibits tumour growth and liver metastasis in colorectal carcinoma", EUROPEAN JOURNAL OF CANCER, vol. 41, no. 12, 1 August 2005 (2005-08-01), Elsevier, Amsterdam NL, pages 1802 - 1810, XP027785674, ISSN: 0959-8049 * |
Also Published As
Publication number | Publication date |
---|---|
CA3189430A1 (en) | 2022-01-27 |
US20230288399A1 (en) | 2023-09-14 |
KR20230107484A (ko) | 2023-07-17 |
JP2023535280A (ja) | 2023-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010120143A2 (ko) | 간암 예후 마커 | |
WO2017026843A1 (ko) | 만성골수성백혈병에 관한 정보 제공 방법 | |
WO2017217807A2 (ko) | Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물 | |
WO2021086014A1 (ko) | 폐암 환자의 면역치료 반응성 예측용 cxcl13 마커 및 이의 용도 | |
WO2018026190A1 (ko) | 암 예후 예측용 바이오마커 | |
WO2011081421A9 (en) | Complement c9 as markers for the diagnosis of cancer | |
WO2014014157A1 (ko) | 위암 진단 및 치료를 위한 adcy3의 용도 | |
WO2022019626A1 (ko) | 대장암 전이 억제제 스크리닝 방법 | |
AU2010200731A1 (en) | Novel compositions and methods in cancer associated with altered expression of PRLR | |
WO2018105921A2 (ko) | 지방간의 진단 또는 치료를 위한 류신 지퍼 단백질의 용도 | |
KR100948808B1 (ko) | 간암 마커로서의 lcn2 유전자, 단백질 및 간암 진단키트 | |
WO2018048257A1 (ko) | 간섬유화 진단용 마커로서의 akap12의 용도 | |
WO2021025412A1 (ko) | 보체 성분 c8 감마를 이용한 알츠하이머병의 진단방법 | |
KR20030051871A (ko) | 항암제에 대한 종양 세포의 감수성을 검정하는 방법 | |
WO2009131366A2 (ko) | 위암 또는 대장암 진단 마커 및 치료제로서의 cdca5 | |
EP4184166A1 (en) | Method for screening colorectal cancer metastasis inhibitor | |
WO2019103456A2 (ko) | Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 | |
WO2019088348A1 (ko) | Egfr 저해제 저항성 암 치료제 | |
WO2023287079A1 (ko) | Csde1을 유효성분으로 포함하는 삼중음성유방암 전이 예측용 바이오마커 조성물 | |
WO2022231102A1 (ko) | 항암제 반응성 예측용 바이오마커 및 이의 용도 | |
WO2010140824A9 (ko) | 간세포암의 진단 및 예후결정용 조성물 | |
CN112359111B (zh) | Prcc或其上调剂在肝癌治疗中的应用及prcc在肝癌诊断或预后中的应用 | |
WO2016200120A1 (ko) | 교모세포종 환자에서 이브루티닙 감수성과 관련된 유전자 및 그 용도 | |
KR102202120B1 (ko) | 알츠하이머 질환의 진단 또는 치료를 위한 Ube2h의 용도 | |
WO2023101316A1 (ko) | Axl을 포함하는 지방간 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21845811 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022579115 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3189430 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021845811 Country of ref document: EP Effective date: 20230220 |